Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$1.0 million.

  • Barinthus Biotherapeutics' Change in Account Payables fell 36624.04% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year increase of 504.72%. This contributed to the annual value of $898000.0 for FY2024, which is 12658.38% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Change in Account Payables stood at -$1.0 million, which was down 36624.04% from $342000.0 recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Change in Account Payables ranged from a high of $2.3 million in Q3 2023 and a low of -$3.8 million during Q4 2023
  • Moreover, its 5-year median value for Change in Account Payables was -$524000.0 (2024), whereas its average is -$353789.5.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Change in Account Payables surged by 97543.86% in 2022, and later plummeted by 48026.05% in 2023.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Change in Account Payables stood at -$114000.0 in 2021, then soared by 975.44% to $998000.0 in 2022, then plummeted by 480.26% to -$3.8 million in 2023, then surged by 87.88% to -$460000.0 in 2024, then crashed by 126.3% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, $342000.0 for Q2 2025, and -$1.2 million during Q1 2025.